¼¼°èÀÇ Àΰ£ ¸ÞŸ´º¸ð¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå º¸°í¼­(2025³â)
Human Metapneumovirus Diagnostics Global Market Report 2025
»óǰÄÚµå : 1760555
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,235,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,013,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,790,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Àΰ£ ¸ÞŸ´º¸ð¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È 10.1%ÀÇ ¿¬Æò±Õ ¼ºÀå·üÀ» ±â·ÏÇϸç 2029³â¿¡´Â 7¾ï 9,000¸¸ ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ¼ºÀåÀº Á¶±â ¹× Á¤È®ÇÑ È£Èí±â °¨¿° Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÇöÀå Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ È®´ë, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÀÇ·á Á¢±Ù¼º È®´ë, ÆÒµ¥¹Í ´ëÀÀ¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ °ü½É, ´ÙÁß È£Èí±â ÆÐ³ÎÀÇ ÅëÇÕ È®´ë µîÀÌ ¹è°æÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹è°æÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ÀÚµ¿È­ ¹× °í󸮷® Áø´Ü ½Ã½ºÅÛ °³¹ß, ºÐ»êÇü Áø´Ü ¸ðµ¨·ÎÀÇ Àüȯ, Áø´Ü ÇØ¼®¿¡ ÀΰøÁö´É Ȱ¿ë, ÀçÅà °Ë»ç ŰƮ äÅà Ȯ´ë, »óÀå»ç¿Í ºñ»óÀå»çÀÇ Çù·Â °ü°è È®´ë µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.

È£Èí±â °¨¿°ÁõÀÇ Áõ°¡´Â Àΰ£ ¸ÞŸ´º¸ð¹ÙÀÌ·¯½º Áø´ÜÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ÙÀÌ·¯½º, ¹ÚÅ׸®¾Æ ¹× ±âŸ º´¿øÃ¼¿¡ ÀÇÇÑ È£Èí±â °¨¿°Àº ºÎºñµ¿, ÀεÎ, ±âµµ ¹× Æó¸¦ Æ÷ÇÔÇÑ È£Èí±â °èÅë¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. À¯º´·üÀÇ Áõ°¡´Â À¯ÇØÇÑ ¿À¿°¹°Áú¿¡ ´ëÇÑ ³ëÃâÀÌ È£Èí±â¸¦ ÀÚ±ØÇÏ°í ¾àÈ­½ÃÄÑ °¨¿°¿¡ Ãë¾àÇÏ°Ô ¸¸µå´Â °Í°ú °ü·ÃÀÌ ÀÖ´Â °ÍÀ¸·Î »ý°¢µË´Ï´Ù. Àΰ£¸ÞŸ´º¸ð¹ÙÀÌ·¯½º Áø´Ü¾àÀº È£Èí±â °¨¿°ÁõÀÇ ¿øÀÎÀ¸·Î hMPV¸¦ ½Äº°ÇÏ¿© Á¤È®ÇÑ Ä¡·á¿Í ´õ ³ªÀº °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 1¿ù ¿µ±¹ º¸°Ç¾ÈÀü±¹Àº 2023-2024³â ½ÃÁ𠵿¾È ¿µ±¹ÀÇ È£Èí±â °¨¿°·üÀÌ 2023³â 50ÁÖ¿Í 52ÁÖ¿¡ 10¸¸ ¸í´ç 8¸íÀ¸·Î Á¤Á¡À» Âï°í, 2024³â 4ÁÖ¿¡´Â 10¸¸ ¸í´ç 10.2¸íÀ¸·Î ´õ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù.¿¡¼­ÀÇ ±Þ¼º È£Èí±â °¨¿° ¹ß»ý °Ç¼ö´Â 2,051°Ç¿¡ À̸£·¶À¸¸ç, ´ëºÎºÐÀÇ »ç·Ê°¡ ¿ä¾ç½Ã¼³°ú º´¿ø¿¡¼­ º¸°íµÇ¾ú´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ·¯ÇÑ È£Èí±â °¨¿°ÁõÀÇ È®»êÀº Àΰ£¸ÞŸ´º¸ð¹ÙÀÌ·¯½º Áø´ÜÁ¦ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

Àΰ£ ¸ÞŸ´º¸ð¹ÙÀÌ·¯½º Áø´ÜÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº È£Èí±â ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR) Áø´Ü µµ±¸¿Í °°Àº Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç °³¹ß¿¡ ÁýÁßÇÏ¸ç ´Ù¾çÇÑ È£Èí±â º´¿øÃ¼¸¦ °ËÃâÇÏ´Â ºÐÀÚÁø´Ü ¿ª·®À» °­È­Çϰí ÀÖ½À´Ï´Ù. È£Èí±â PCR Áø´Ü ¼Ö·ç¼ÇÀº È£Èí±â º´¿øÃ¼ÀÇ À¯Àü¹°ÁúÀ» °í°¨µµ, °íƯÀ̼ºÀ¸·Î ÁõÆøÇÏ¿© °ËÃâ ¹× µ¿Á¤ÇÏ´Â ºÐÀÚ °Ë»ç¹ýÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 3¿ù Áß±¹ ¼ÒÀç ºÐÀÚÁø´Ü ȸ»çÀÎ Jiangsu BioPerfectus Technologies Co, Ltd.´Â È£Èí±â º´¿øÃ¼ ´ÙÁß ½Ç½Ã°£ PCR Áø´Ü ŰƮ¸¦ Ãâ½ÃÇÏ¿´½À´Ï´Ù. ÀÌ ¼Ö·ç¼ÇÀº ¿©·¯ È£Èí±â º´¿øÃ¼¸¦ µ¿½Ã¿¡ ³ôÀº Á¤È®µµ·Î ½Å¼ÓÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾î ÀÓ»ó ÇöÀå°ú Áø·á ÇöÀå¿¡¼­ Áø´Ü È¿À²À» Çâ»ó½Ãŵ´Ï´Ù. ±¤¹üÀ§ÇÑ Àû¿ë ¹üÀ§¿Í Á¤È®ÇÑ ¼º´ÉÀº ƯÈ÷ Áõ»óÀÌ Áߺ¹µÇ´Â È£Èí±â °¨¿°ÁõÀÇ °ü¸®¿¡¼­ Àû½Ã¿¡ ÀÓ»óÀû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ Å« µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Human metapneumovirus (hMPV) diagnostics involve the methods and criteria used to detect and confirm infection with human metapneumovirus, a respiratory pathogen that can cause illnesses ranging from mild cold-like symptoms to severe respiratory infections, particularly in children, the elderly, and immunocompromised individuals.

The primary product types in human metapneumovirus diagnostics are reagents and kits, as well as instruments. Reagents and kits are essential laboratory products that contain chemical substances and tools for performing specific diagnostic tests or experiments. The diagnostic test types include molecular diagnostics, immunodiagnostics, culture-based methods, and others, utilizing technologies such as PCR-based diagnostics, next-generation sequencing (NGS), immunofluorescence assays, lateral flow assays, microarray technology, and others. These tests are used in various settings, including hospitals and clinics, diagnostic and reference laboratories, academic and research institutions, among others.

The human metapneumovirus diagnostics market research report is one of a series of new reports from The Business Research Company that provides human metapneumovirus diagnostics market statistics, including human metapneumovirus diagnostics industry global market size, regional shares, competitors with a human metapneumovirus diagnostics market share, detailed human metapneumovirus diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the human metapneumovirus diagnostics industry. This human metapneumovirus diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human metapneumovirus diagnostics market size has grown rapidly in recent years. It will grow from $0.49 billion in 2024 to $0.54 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historical period can be attributed to an increase in pediatric hospitalization rates due to respiratory infections, heightened awareness of viral respiratory pathogens, the initial adoption of molecular diagnostic tools, the expansion of public health surveillance programs, and greater funding for pediatric respiratory diseases.

The human metapneumovirus diagnostics market size is expected to see rapid growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth anticipated in the forecast period is driven by rising demand for early and accurate respiratory infection diagnostics, growing investments in point-of-care diagnostic solutions, expanding healthcare access in emerging markets, a global focus on pandemic preparedness, and greater integration of multiplex respiratory panels. Key trends in the forecast period include the development of automated and high-throughput diagnostic systems, a shift toward decentralized diagnostic models, the use of artificial intelligence in diagnostic interpretation, the increasing adoption of at-home testing kits, and growing collaboration between public and private diagnostic companies.

The increasing prevalence of respiratory infections is expected to drive growth in the human metapneumovirus diagnostics market. Respiratory infections, caused by viruses, bacteria, or other pathogens, affect the respiratory system, including the sinuses, throat, airways, and lungs. The rising prevalence can be linked to the exposure to harmful pollutants that irritate and weaken the respiratory tract, making it more susceptible to infections. Human metapneumovirus diagnostics help identify hMPV as the cause of respiratory infections, allowing for accurate treatment and better management. For example, in January 2025, the UK Health Security Agency reported that during the 2023-2024 season, respiratory infection rates in England peaked at 8.0 per 100,000 in weeks 50 and 52 of 2023, and rose further to 10.2 per 100,000 in week 4 of 2024, while acute respiratory infection incidents in closed settings reached 2,051, with most cases reported in care homes and hospitals. This growing prevalence of respiratory infections is fueling the expansion of the human metapneumovirus diagnostics market.

Leading companies in the human metapneumovirus diagnostics market are focusing on developing innovative solutions, such as respiratory polymerase chain reaction (PCR) diagnostic tools, to enhance molecular diagnostic capabilities for detecting a wide range of respiratory pathogens. A respiratory PCR diagnostic solution is a molecular testing method used to detect and identify respiratory pathogens by amplifying their genetic material with high sensitivity and specificity. For example, in March 2023, Jiangsu BioPerfectus Technologies Co., Ltd., a molecular diagnostic company based in China, launched its respiratory pathogen multiplex real-time PCR diagnostic kit. This solution is designed to simultaneously detect multiple respiratory pathogens with high accuracy and a rapid turnaround time, improving diagnostic efficiency in clinical and point-of-care settings. Its broad coverage and precise performance significantly aid timely clinical decision-making, particularly for managing respiratory infections with overlapping symptoms.

In February 2024, AstraZeneca plc, a pharmaceutical company based in the UK, acquired Icosavax Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to enhance its late-stage pipeline and expand its expertise in vaccines for respiratory conditions with high burdens, specifically advancing Icosavax's lead investigational combination vaccine candidate, IVX-A12, which targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Icosavax Inc., a biotechnology company based in the US, focuses on developing vaccines, especially combination vaccines targeting respiratory viruses such as RSV and hMPV.

Major players in the human metapneumovirus diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Quest Diagnostics, Hologic Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, Qiagen NV, Diasorin, Luminex Corporation, bioMerieux, Seegene Inc., Cepheid, R-Biopharm AG, Certest Biotec, ZeptoMetrix, Xi'an Tianlong Science and Technology Co. Ltd, The Native Antigen Company, Hangzhou Testsea Biotechnology Co. Ltd., and Attogene.

North America was the largest region in the human metapneumovirus diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human metapneumovirus diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human metapneumovirus diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human metapneumovirus diagnostics market consists of revenues earned by entities by providing services such as diagnostic testing services, clinical laboratory services, point-of-care testing services, home sample collection services, public health surveillance services, and contract research and testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus diagnostics market also includes sales of sample collection devices, diagnostic data management tools, test validation kits, and safety and waste disposal systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Metapneumovirus Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human metapneumovirus diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for human metapneumovirus diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human metapneumovirus diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Human Metapneumovirus Diagnostics Market Characteristics

3. Human Metapneumovirus Diagnostics Market Trends And Strategies

4. Human Metapneumovirus Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Metapneumovirus Diagnostics Growth Analysis And Strategic Analysis Framework

6. Human Metapneumovirus Diagnostics Market Segmentation

7. Human Metapneumovirus Diagnostics Market Regional And Country Analysis

8. Asia-Pacific Human Metapneumovirus Diagnostics Market

9. China Human Metapneumovirus Diagnostics Market

10. India Human Metapneumovirus Diagnostics Market

11. Japan Human Metapneumovirus Diagnostics Market

12. Australia Human Metapneumovirus Diagnostics Market

13. Indonesia Human Metapneumovirus Diagnostics Market

14. South Korea Human Metapneumovirus Diagnostics Market

15. Western Europe Human Metapneumovirus Diagnostics Market

16. UK Human Metapneumovirus Diagnostics Market

17. Germany Human Metapneumovirus Diagnostics Market

18. France Human Metapneumovirus Diagnostics Market

19. Italy Human Metapneumovirus Diagnostics Market

20. Spain Human Metapneumovirus Diagnostics Market

21. Eastern Europe Human Metapneumovirus Diagnostics Market

22. Russia Human Metapneumovirus Diagnostics Market

23. North America Human Metapneumovirus Diagnostics Market

24. USA Human Metapneumovirus Diagnostics Market

25. Canada Human Metapneumovirus Diagnostics Market

26. South America Human Metapneumovirus Diagnostics Market

27. Brazil Human Metapneumovirus Diagnostics Market

28. Middle East Human Metapneumovirus Diagnostics Market

29. Africa Human Metapneumovirus Diagnostics Market

30. Human Metapneumovirus Diagnostics Market Competitive Landscape And Company Profiles

31. Human Metapneumovirus Diagnostics Market Other Major And Innovative Companies

32. Global Human Metapneumovirus Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Metapneumovirus Diagnostics Market

34. Recent Developments In The Human Metapneumovirus Diagnostics Market

35. Human Metapneumovirus Diagnostics Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â